

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20807-002US1	Application No. 10/577,535
	Applicant Bing Zhu		
	Filing Date April 27, 2006	Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AR	Greil et al., <i>Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools</i> , Journal of Leukocyte Biology, Vol. 74, pp. 311-330 (September 2003)
	AS	LeBlanc and Ashkenazi, <i>Apo2L/TRAIL and its death and decoy receptors</i> , Cell Death and Differentiation, pp. 66-75 (2003)
	AT	Walczak et al., <i>Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo</i> , Nature Medicine, Vol. 5, No. 2, pp. 157-163 (February 1999)
	AU	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	